GT-UGT1A1-AAV8-02
Phase 2Gene therapy
GT-UGT1A1-AAV8-02 is one of 4 small molecule programs targeting Gene Therapy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Gene Therapy
#DrugCompanyPhaseTrials
1Busulfex
Akero TherapeuticsPhase 2
BMN 333
BioMarin PharmaceuticalPhase 2
GT-UGT1A1-AAV8-02
FFederal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
Phase 2
Raav2-ND4
BBin Li
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gene Therapy1 trial
Gene Therapy for Crigler Najjar Syndrome Type I (AlphaCN)
Recruiting·FFederal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare·Phase 1/2·NCT06641154·5 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GT-UGT1A1-AAV8-02. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details